Because the 0.9% benzyl alcohol preservative allows repeated withdrawals without re-sterilising the vial, a single 10ml supply can support multiple reconstitution events across a single research project, reducing both cost and vial waste compared to single-use sterile water for injection.
For some people, this can result in mild digestive symptoms such as nausea, constipation, or bloating
This triple-action mechanism distinguishes it from existing approved agents such as semaglutide (a GLP-1 receptor agonist, approved in the UK as Wegovy and Ozempic) and tirzepatide (a dual GIP/GLP-1 agonist, approved as Mounjaro)
These assist in boosting antioxidant levels within the body while also providing healthy, glowing skin
Acknowledgements This work was supported by the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre